1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Erenumab
Trade Name:
Aimovig
Manufacturer/Distributor:
Novartis Pharmaceuticals Canada Inc.
Classification:
Anti-calcitonin gene-related peptide receptor
Antimigraine agent
ATC Class:
N02CX07 - erenumab
Status:
active
Notice of Compliance (yyyy/mm/dd):
2018/08/01
Date Marketed in Canada (yyyy/mm/dd):
2018/08/01
Presentation:
Injection: 70 mg/mL. DIN: 02479605
Injection pen: 70 mg/pen. DIN: 02479613
Comments:
For prevention of migraine in adults who have at least 4 migraine days per month.
Back to:
Drug Product Listings 
